| Followers | 192 |
| Posts | 28794 |
| Boards Moderated | 13 |
| Alias Born | 04/03/2002 |
Thursday, May 30, 2019 2:41:51 PM
The new presentation on the BIXT website is quite impressive. Note also that in addition to the latest advancements in stroke treatments, the company is also making significant contributions in the area of wound healing.
See here:
http://www.bioxytraninc.com/wound-healing/
Wound Healing
Wound healing is the process by which skin or other body tissue repairs itself after trauma. In undamaged skin, the epidermis (surface layer) and dermis (the deeper layer) form a protective barrier against the external environment. When the barrier is broken, an orchestrated cascade of biochemical events is set into motion to repair the damage. This process is divided into predictable phases: hemostasis (blood clotting), inflammation, tissue growth and proliferation, and tissue remodeling or maturation.The wound healing process is both complex and fragile, and it is susceptible to interruption or failure, leading to the formation of non-healing chronic wounds. Factors that contribute to non-healing chronic wounds are diabetes, venous or arterial disease, infection, and metabolic deficiencies of old age.Advancements in the clinical understanding of wounds and their pathophysiology have commanded significant biomedical innovations in the treatment of acute, chronic, and other types of wounds. Many biologics, skin substitutes, bio-membranes, and scaffolds have been developed to facilitate wound healing through various mechanisms (2). Wound healing is a complex and dynamic process of restoring cellular structure and tissue layers. Future advances in wound healing will focus on the agents that influence the repair of damaged tissue. This may include laser techniques, stem cells, fetal tissue, and other modalities that enhance the proliferation and migration of cells, and acceleration of the healing process (3).
BioXyTran Inc.’s product BXT-252 can improve the supply of oxygen to wounded tissue and potentially accelerate healing. It can be applied together with any of the above treatment modalities.
(2) Vyas KS, Vasconez HC. Wound Healing: Biologics, Skin Substitutes, Biomembranes and Scaffolds. Healthcare. 2014; 2(3): 356-400
(3) The 2015 Physician’s Guide to the Wound Institute®
See here:
http://www.bioxytraninc.com/wound-healing/
Wound Healing
Wound healing is the process by which skin or other body tissue repairs itself after trauma. In undamaged skin, the epidermis (surface layer) and dermis (the deeper layer) form a protective barrier against the external environment. When the barrier is broken, an orchestrated cascade of biochemical events is set into motion to repair the damage. This process is divided into predictable phases: hemostasis (blood clotting), inflammation, tissue growth and proliferation, and tissue remodeling or maturation.The wound healing process is both complex and fragile, and it is susceptible to interruption or failure, leading to the formation of non-healing chronic wounds. Factors that contribute to non-healing chronic wounds are diabetes, venous or arterial disease, infection, and metabolic deficiencies of old age.Advancements in the clinical understanding of wounds and their pathophysiology have commanded significant biomedical innovations in the treatment of acute, chronic, and other types of wounds. Many biologics, skin substitutes, bio-membranes, and scaffolds have been developed to facilitate wound healing through various mechanisms (2). Wound healing is a complex and dynamic process of restoring cellular structure and tissue layers. Future advances in wound healing will focus on the agents that influence the repair of damaged tissue. This may include laser techniques, stem cells, fetal tissue, and other modalities that enhance the proliferation and migration of cells, and acceleration of the healing process (3).
BioXyTran Inc.’s product BXT-252 can improve the supply of oxygen to wounded tissue and potentially accelerate healing. It can be applied together with any of the above treatment modalities.
(2) Vyas KS, Vasconez HC. Wound Healing: Biologics, Skin Substitutes, Biomembranes and Scaffolds. Healthcare. 2014; 2(3): 356-400
(3) The 2015 Physician’s Guide to the Wound Institute®
Recent BIXT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 05:28:48 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 08:01:16 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2026 10:23:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 01:05:14 PM
- BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT • GlobeNewswire Inc. • 03/20/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 08:00:24 PM
- Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M • GlobeNewswire Inc. • 03/04/2026 08:40:00 PM
- Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 • ACCESS Newswire • 03/02/2026 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 02:22:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 11:20:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 11:04:17 AM
- Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran • GlobeNewswire Inc. • 02/11/2026 11:00:00 AM
- Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics • GlobeNewswire Inc. • 02/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 10:01:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2025 11:15:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:15:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:02:52 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/18/2025 06:12:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:00:57 PM
- Bioxytran Announces Initiation of Coverage of its Stock by Independent Research • GlobeNewswire Inc. • 11/13/2025 06:50:00 PM
- Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug • GlobeNewswire Inc. • 10/29/2025 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2025 11:01:03 AM
